Search Results | Blood | American Society of Hematology

1-20 of 123

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Assessment of Minimal Residual Disease in a Phase 1b Study of Once-Weekly Carfilzomib Combined with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma

Ola Landgren, MD PhD, Melissa Alsina, MD, Noa Biran, MD, David H. Vesole, MD PhD, Paul K. Wallace, MS, PhD, Belle Fang, Gregory Arnold, Amy Kimball, MD PhD, David S. Siegel, MD PhD

Blood (2020) 136 (Supplement 1): 28.

DOI: https://doi.org/10.1182/blood-2020-133803

Published: 2020

Journal Articles

Prospective Randomized Comparative Study of Myeloablative Fludarabine/Busulfan (Flu/Bu4) and Fludarabine/Busulfan/Total Body Irradiation (Flu/Bu4/TBI) Conditioning Regimen for Patients with Myeloid Diseases

Hyung C. Suh, MDPhD, Scott D. Rowley, MD, Sukhdeep Kaur, MD, Brittany Lukasik, Phyllis McKiernan, Michele Boonstra, APN, Milissa Baker, MSN, ANP, Mary E Dilorenzo, APN, Alan Skarbnik, MD, Themba Nyirenda, PhD, David H. Vesole, MD PhD, Michele L. Donato, MD

Blood (2020) 136 (Supplement 1): 9.

DOI: https://doi.org/10.1182/blood-2020-142272

Published: 2020

Journal Articles

Evomela® Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation

Marshall McKenna, MD, Phyllis McKiernan, David S. Siegel, Scott D. Rowley, MD, Noa Biran, MD, David H. Vesole, MD PhD, Stuart L. Goldberg, MD, Themba Nyirenda, PhD, Andrew L. Pecora, MD, Andre Goy, MD, Michele L. Donato, MD

Blood (2019) 134 (Supplement_1): 3316.

DOI: https://doi.org/10.1182/blood-2019-132114

Published: 2019

Journal Articles

Elotuzumab As Post-Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Myeloma

Nikhita Gadi, MDMSc, Linda Schmidt, RN, Jaeil Ahn, PhD, Tianmin Wu, MS, Scott D. Rowley, MD, Elli Gourna Paleoudis, PhD, Michele L. Donato, MD, David H. Vesole, MD PhD, Stuart L. Goldberg, MD, David S. Siegel, Noa Biran, MD

Blood (2019) 134 (Supplement_1): 3141.

DOI: https://doi.org/10.1182/blood-2019-129504

Published: 2019

Journal Articles

Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients

Sudarsan Kollimuttathuliam, MD, Phyllis McKiernan, David S. Siegel, Scott D. Rowley, MD, Noa Biran, MD, David H. Vesole, MD PhD, Themba Nyirenda, PhD, Andrew L. Pecora, MD, Stuart L. Goldberg, MD, Andre Goy, MD, Michele L. Donato, MD

Blood (2019) 134 (Supplement_1): 4576.

DOI: https://doi.org/10.1182/blood-2019-132052

Published: 2019

Journal Articles

Sustained Hematopoietic Recovery after Salvage Autologous Stem Cell Transplants after Long Term Storage of Cryopreserved Hematopoietic Progenitor Stem Cells (HPSC)

Sarah S. Makhani, BA, Ronit Reich-Slotky, PhD, Pashna N. Munshi, MD, Noa Biran, MD, Michele L. Donato, MD, Stuart L. Goldberg, MD, Andrew L. Pecora, MD, David S. Siegel, David H. Vesole, MD PhD, Scott D. Rowley, MD

Blood (2019) 134 (Supplement_1): 4475.

DOI: https://doi.org/10.1182/blood-2019-122111

Published: 2019

Journal Articles

Severe Infections and Antibiotic Use Negatively Impact Progression Free and Overall Survival of Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Marshall McKenna, MD, Rena Feinman, PhD, Jaeil Ahn, PhD, Shuqi Wang, MSc, Elli Gourna Paleoudis, PhD, David H. Vesole, MD PhD, Stuart L. Goldberg, MD, Jun Chih Wang, MD, Abdul Rehman, MD, Giselle Alexandra Suero-Abreu, MD PhD, Phyllis McKiernan, Michele L. Donato, MD, Scott D. Rowley, MD, David S. Siegel, Noa Biran, MD

Blood (2019) 134 (Supplement_1): 5510.

DOI: https://doi.org/10.1182/blood-2019-132134

Published: 2019

Journal Articles

Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma

Pashna N. Munshi, MD, Parameswaran Hari, MBBS, MD, David H. Vesole, MD PhD, Artur Jurczyszyn, MD, Jan Zaucha, MD PhD, Omar Davila, Shaji K. Kumar, MD, Nina D. Shah, MD, Muzaffar H. Qazilbash, MD, Anita D'Souza, MDMS

Blood (2019) 134 (Supplement_1): 782.

DOI: https://doi.org/10.1182/blood-2019-124804

Published: 2019

Journal Articles

Two Year Update of Phase II Trial of Pembrolizumab, Lenalidomide and Dexamethasone As Post -Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Meena Bansal, DO, David S. Siegel, Jaeil Ahn, PhD, Rena Feinman, PhD, David H. Vesole, MD PhD, Joshua R Richter, MD, Andrew L. Pecora, MD, Elli Gourna Paleoudis, PhD, Scott D. Rowley, MD, Michele L. Donato, MD, Robert Korngold, PhD, Palka Anand, RN, BSN, CCRP, Laura McBride, RN, BSN, OCN, Kristin Ivanovski, RN, BSN, CCRP, Noa Biran, MD

Blood (2019) 134 (Supplement_1): 1911.

DOI: https://doi.org/10.1182/blood-2019-125155

Published: 2019

Journal Articles

Busulfan, Melphalan, and Bortezomib Compared to Single Agent High-Dose Melphalan As a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Long Term Follow up of a Novel Conditioning Regimen

Patrick Hagen, MD, Anita D'Souza, MDMS, Parameswaran Hari, MBBS, MD, Omar Davila, Mei-Jie Zhang, David H. Vesole, MD PhD, Scott E. Smith, MD PhD, Tulio E Rodriguez, MD, Patrick J. Stiff, MD

Blood (2019) 134 (Supplement_1): 2023.

DOI: https://doi.org/10.1182/blood-2019-124188

Published: 2019

Journal Articles

Comparison of Peripheral Blood Stem Cell Mobilization for Multiple Myeloma Patients over 70 Years of Age with Younger Patients

Ning Dong, MD, David S Siegel, MD PhD, Phyllis McKiernan, Noa Biran, MD, Alan P Skarbnik, MD, David H. Vesole, MD PhD, Andrew L. Pecora, MD, Scott D. Rowley, MD, Michele L. Donato, MD

Blood (2018) 132 (Supplement 1): 4554.

DOI: https://doi.org/10.1182/blood-2018-99-117498

Published: 2018

Journal Articles

The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?

Blood (2018) 132 (Supplement 1): 4452.

DOI: https://doi.org/10.1182/blood-2018-99-115971

Published: 2018

Journal Articles

Multiple Myeloma Staging in Real World Clinical Practice Is Suboptimal: Absence of Beta-2-Microglobulin and Serum Lactase Dehydrogenase Testing Are Limiting Factors

Noa Biran, MD, Sukhmani Gill, MD, Andrew D Norden, MD MPH MBA, David H. Vesole, MD PhD, Wallace G Stephen, MD, Kenneth D Nahum, DO, David S Siegel, MD PhD, Stuart L. Goldberg, MD

Blood (2018) 132 (Supplement 1): 5587.

DOI: https://doi.org/10.1182/blood-2018-99-119559

Published: 2018

Journal Articles

Prospective Analysis of Bortezomib, Fludarabine and Melphalan As Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation for Multiple Myeloma

Phyllis McKiernan, David S Siegel, MD PhD, David H. Vesole, MD PhD, Tracy Andrews, MSc, Noa Biran, MD, Scott D. Rowley, MD, Alan P Skarbnik, MD, Andrew L. Pecora, MD, Jacquelyn Callahan, RN, Andrea Ortega, RN, Mariefel Vendivil, RN, Supreet Kaur, MD, Marshall McKenna, MD, Michele L. Donato, MD

Blood (2018) 132 (Supplement 1): 1020.

DOI: https://doi.org/10.1182/blood-2018-99-117313

Published: 2018

Journal Articles

FISH Abnormalities (including R-ISS defining and IgH mutations) Are Similar across Race and Ethnicity Among Patients with Multiple Myeloma (except higher rates of t(4:14) in Minorities and 1q Amplifications in Asian/Indians)

Noa Biran, MD, Camille Johnson, MD, Andrew D Norden, MD MPH MBA, Roger Kumar, BS MS, David H. Vesole, MD PhD, Seth H. Berk, MD, Denis B. Fitzgerald, MD, David S Siegel, MD PhD, Stuart L. Goldberg, MD

Blood (2018) 132 (Supplement 1): 5608.

DOI: https://doi.org/10.1182/blood-2018-99-119744

Published: 2018

Journal Articles

The Prognostic Impact of t(14;20) in Multiple Myeloma - a Multicenter Retrospective Study of 26 Patients

Artur Jurczyszyn, MD, Sarah Goldman-Mazur, MD, Jorge J. Castillo, MD, Anna Waszczuk-Gajda, Norbert Grząśko, MD PhD, Max Bittrich, MD, Andrew J Yee, MD, Anna Suska, MD, Deepu Madduri, MD, Saurabh Chhabra, MD, Ariel Kleman, MD, Parameswaran Hari, MBBS, MD, Stuart L. Goldberg, MD, Aimee Chappell, Massimo Gentile, David H. Vesole, MD PhD

Blood (2018) 132 (Supplement 1): 5600.

DOI: https://doi.org/10.1182/blood-2018-99-115816

Published: 2018

Journal Articles

Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematological Malignancies — CPIT-001 Trial

Alan P Skarbnik, MD, Michele L. Donato, MD, Robert Korngold, PhD, Rena Feinman, PhD, Scott D. Rowley, MD, Andre Goy, MD, David H. Vesole, MD PhD, Pashna N. Munshi, MD, David S Siegel, MD PhD, Tatyana A. Feldman, MD, Noa Biran, MD, Lori A. Leslie, MD, Michael B Atkins, MD, Andrew L. Pecora, MD

Blood (2018) 132 (Supplement 1): 256.

DOI: https://doi.org/10.1182/blood-2018-99-113586

Published: 2018

Journal Articles

Evaluation of Treg and Memory T Cell Profiles, Post-ASCT with Early Combination Nivolumab/Ipilimumab Therapy, in Patients with Multiple Myeloma (MM) and Diffuse Large B Cell Lymphoma (DLBCL)

Dante B. Descalzi-Montoya, PhD, Zheng Yang, MS, Kira Goldgirsh, MS, Rena Feinman, PhD, Stacey L. Fanning, PhD, David H. Vesole, MD PhD, Pashna N. Munshi, MD, Michael B Atkins, MD, Scott D. Rowley, MD, Noa Biran, MD, David S Siegel, MD PhD, Andre Goy, MD, Tatyana A. Feldman, MD, Lori A. Leslie, MD, Michele L. Donato, MD, Alan P Skarbnik, MD, Andrew L. Pecora, MD, Robert Korngold, PhD

Blood (2018) 132 (Supplement 1): 3421.

DOI: https://doi.org/10.1182/blood-2018-99-120240

Published: 2018

Journal Articles

Influence of the Gut Microbiome on Clinical Outcomes in the CPIT-001 Trial, a Phase Ib-IIA Study of Combined Checkpoint Inhibition with Nivolumab and Ipilimumab after Autologous Hematopoietic Stem Cell Transplantation in Patients at High-Risk for Post-Transplant Recurrence

Rena Feinman, PhD, Tracy Andrews, MSc, Iriana Colorado, MSc, Joshua Zenreich, Suzanne Kosky, BS, Themba Nyirenda, PhD, Noa Biran, MD, David S Siegel, MD PhD, David H. Vesole, MD PhD, Michele L. Donato, MD, Scott D. Rowley, MD, Pashna N. Munshi, MD, Michael B Atkins, MD, Tatyana A. Feldman, MD, Lori A. Leslie, MD, Andre Goy, MD, Robert Korngold, PhD, Alan P Skarbnik, MD, Andrew L. Pecora, MD

Blood (2018) 132 (Supplement 1): 3443.

DOI: https://doi.org/10.1182/blood-2018-99-117669

Published: 2018

Journal Articles

Largest Reported Series of Adults Who Received Treatment with Eculizumab (ECU) for Hematopoietic Cell Transplantation-Associated Thrombotic Microangiopathy (TA-TMA). a Single Center Experience

Alan P Skarbnik, MD, Mary E Dilorenzo, APN, Michele Simone, APN, Scott D. Rowley, MD, David H. Vesole, MD PhD, Maribel Pereiras, Pharm D, Tracy Andrews, MSc, Andrew L. Pecora, MD, Michele L. Donato, MD

Blood (2018) 132 (Supplement 1): 3383.

DOI: https://doi.org/10.1182/blood-2018-99-113639

Published: 2018

2 3 4 5

NARROW

Assessment of Minimal Residual Disease in a Phase 1b Study of Once-Weekly Carfilzomib Combined with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma

Prospective Randomized Comparative Study of Myeloablative Fludarabine/Busulfan (Flu/Bu4) and Fludarabine/Busulfan/Total Body Irradiation (Flu/Bu4/TBI) Conditioning Regimen for Patients with Myeloid Diseases

Evomela® Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation

Elotuzumab As Post-Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Myeloma

Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients

Sustained Hematopoietic Recovery after Salvage Autologous Stem Cell Transplants after Long Term Storage of Cryopreserved Hematopoietic Progenitor Stem Cells (HPSC)

Severe Infections and Antibiotic Use Negatively Impact Progression Free and Overall Survival of Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma

Two Year Update of Phase II Trial of Pembrolizumab, Lenalidomide and Dexamethasone As Post -Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Busulfan, Melphalan, and Bortezomib Compared to Single Agent High-Dose Melphalan As a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Long Term Follow up of a Novel Conditioning Regimen

Comparison of Peripheral Blood Stem Cell Mobilization for Multiple Myeloma Patients over 70 Years of Age with Younger Patients

The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?

Multiple Myeloma Staging in Real World Clinical Practice Is Suboptimal: Absence of Beta-2-Microglobulin and Serum Lactase Dehydrogenase Testing Are Limiting Factors

Prospective Analysis of Bortezomib, Fludarabine and Melphalan As Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation for Multiple Myeloma

FISH Abnormalities (including R-ISS defining and IgH mutations) Are Similar across Race and Ethnicity Among Patients with Multiple Myeloma (except higher rates of t(4:14) in Minorities and 1q Amplifications in Asian/Indians)

The Prognostic Impact of t(14;20) in Multiple Myeloma - a Multicenter Retrospective Study of 26 Patients

Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematological Malignancies — CPIT-001 Trial

Evaluation of Treg and Memory T Cell Profiles, Post-ASCT with Early Combination Nivolumab/Ipilimumab Therapy, in Patients with Multiple Myeloma (MM) and Diffuse Large B Cell Lymphoma (DLBCL)

Influence of the Gut Microbiome on Clinical Outcomes in the CPIT-001 Trial, a Phase Ib-IIA Study of Combined Checkpoint Inhibition with Nivolumab and Ipilimumab after Autologous Hematopoietic Stem Cell Transplantation in Patients at High-Risk for Post-Transplant Recurrence

Largest Reported Series of Adults Who Received Treatment with Eculizumab (ECU) for Hematopoietic Cell Transplantation-Associated Thrombotic Microangiopathy (TA-TMA). a Single Center Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only